喷射流动脉粥样硬化切除术与紫杉醇涂层气球:前瞻性随机JET-RANGER研究的3年结果。

IF 0.9 Q4 PERIPHERAL VASCULAR DISEASE
International Journal of Angiology Pub Date : 2024-10-03 eCollection Date: 2025-03-01 DOI:10.1055/s-0044-1791546
Nicolas W Shammas, Gail Shammas, Sue Jones-Miller
{"title":"喷射流动脉粥样硬化切除术与紫杉醇涂层气球:前瞻性随机JET-RANGER研究的3年结果。","authors":"Nicolas W Shammas, Gail Shammas, Sue Jones-Miller","doi":"10.1055/s-0044-1791546","DOIUrl":null,"url":null,"abstract":"<p><p>The JET-RANGER study (NCT03206762) was a multicenter (11 U.S. centers), randomized trial, core-lab adjudicated and designed to demonstrate the superiority of Jetstream + paclitaxel-coated balloon (JET + PCB) versus percutaneous transluminal angioplasty (PTA) + PCB in treating femoropopliteal arterial disease. The 1- and 2-year outcomes have been recently published. The 3-year outcome data are presented in this report. The JET-RANGER trial initially had 47 patients with 48 lesions. Thirty-one in the JET-PCB arm and 16 in the PTA + PCB arm (2:1 randomization). At 3-year follow-ups, there were 20 patients in the JET-PCB arm and 14 patients in the PTA + PCB arm. Kaplan-Meier survival analysis was performed to estimate the freedom from target lesion revascularization (TLR) at 3 years. Bailout stenting was not considered a TLR in this analysis. Statistical significance was determined by a <i>p</i> -value < 0.05. Freedom from TLR was statistically similar between the two groups at 3 years between JET + PCB and PTA + PCB (freedom from TLR was 88.0 vs. 67.8%, respectively, <i>p</i>  = 0.1380). There was also no significant difference in the change of ankle-brachial index (ABI) between the PTA + PCB and JET + PCB from baseline at 6 months ( <i>p</i>  = 0.7890), 1 year ( <i>p</i>  = 0.4070), 2 years ( <i>p</i>  = 0.7410), and 3 years ( <i>p</i>  = 0.8010). There was also no statistical difference between the JET + PCB and PTA + PCB arms for RCC improvement by one or more categories from baseline to 3 years ( <i>p</i>  = 0.8949). There were no minor or major amputations for either arm throughout the 3-year follow-up. Five JET + PCB patients died before the 3-year specified window and none in the PTA + PCB arm ( <i>p</i>  = 0.137). Two of the deaths were due to cancer and three due to cardiac causes. None were deemed related to the device or procedure. JET + PCB had similar freedom from TLR and improvement in ABI and RCC at 3-year follow-up with no difference in amputation or mortality between the 2 arms. A trend toward less TLR was seen in the JET + PCB arm.</p>","PeriodicalId":13798,"journal":{"name":"International Journal of Angiology","volume":"34 1","pages":"56-59"},"PeriodicalIF":0.9000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813604/pdf/","citationCount":"0","resultStr":"{\"title\":\"Jetstream Atherectomy with Paclitaxel-Coated Balloons: 3-Year Outcomes of the Prospective Randomized JET-RANGER Study.\",\"authors\":\"Nicolas W Shammas, Gail Shammas, Sue Jones-Miller\",\"doi\":\"10.1055/s-0044-1791546\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The JET-RANGER study (NCT03206762) was a multicenter (11 U.S. centers), randomized trial, core-lab adjudicated and designed to demonstrate the superiority of Jetstream + paclitaxel-coated balloon (JET + PCB) versus percutaneous transluminal angioplasty (PTA) + PCB in treating femoropopliteal arterial disease. The 1- and 2-year outcomes have been recently published. The 3-year outcome data are presented in this report. The JET-RANGER trial initially had 47 patients with 48 lesions. Thirty-one in the JET-PCB arm and 16 in the PTA + PCB arm (2:1 randomization). At 3-year follow-ups, there were 20 patients in the JET-PCB arm and 14 patients in the PTA + PCB arm. Kaplan-Meier survival analysis was performed to estimate the freedom from target lesion revascularization (TLR) at 3 years. Bailout stenting was not considered a TLR in this analysis. Statistical significance was determined by a <i>p</i> -value < 0.05. Freedom from TLR was statistically similar between the two groups at 3 years between JET + PCB and PTA + PCB (freedom from TLR was 88.0 vs. 67.8%, respectively, <i>p</i>  = 0.1380). There was also no significant difference in the change of ankle-brachial index (ABI) between the PTA + PCB and JET + PCB from baseline at 6 months ( <i>p</i>  = 0.7890), 1 year ( <i>p</i>  = 0.4070), 2 years ( <i>p</i>  = 0.7410), and 3 years ( <i>p</i>  = 0.8010). There was also no statistical difference between the JET + PCB and PTA + PCB arms for RCC improvement by one or more categories from baseline to 3 years ( <i>p</i>  = 0.8949). There were no minor or major amputations for either arm throughout the 3-year follow-up. Five JET + PCB patients died before the 3-year specified window and none in the PTA + PCB arm ( <i>p</i>  = 0.137). Two of the deaths were due to cancer and three due to cardiac causes. None were deemed related to the device or procedure. JET + PCB had similar freedom from TLR and improvement in ABI and RCC at 3-year follow-up with no difference in amputation or mortality between the 2 arms. A trend toward less TLR was seen in the JET + PCB arm.</p>\",\"PeriodicalId\":13798,\"journal\":{\"name\":\"International Journal of Angiology\",\"volume\":\"34 1\",\"pages\":\"56-59\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813604/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Angiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0044-1791546\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Angiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0044-1791546","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

JET- ranger研究(NCT03206762)是一项多中心(11个美国中心),随机试验,核心实验室评审,旨在证明Jetstream +紫杉醇涂层球囊(JET + PCB)与经皮腔内血管成形术(PTA) + PCB在治疗股腘动脉疾病方面的优势。最近公布了1年和2年的结果。本报告提供了3年的结果数据。JET-RANGER试验最初有47名患者,48个病变。JET-PCB组31例,PTA + PCB组16例(2:1随机分组)。在3年的随访中,JET-PCB组有20例,PTA + PCB组有14例。Kaplan-Meier生存分析用于估计3年目标病变血运重建(TLR)的自由度。在本分析中,救助支架置入不被认为是TLR。p值p = 0.1380)。与基线相比,PTA + PCB与JET + PCB在6个月(p = 0.7890)、1年(p = 0.4070)、2年(p = 0.7410)和3年(p = 0.8010)时的踝臂指数(ABI)变化也无显著差异。从基线到3年,JET + PCB组和PTA + PCB组在一个或多个类别的RCC改善方面也没有统计学差异(p = 0.8949)。在整个3年的随访中,没有任何手臂发生轻微或严重的截肢。5例JET + PCB患者在3年指定窗口前死亡,而PTA + PCB组无患者死亡(p = 0.137)。其中2人死于癌症,3人死于心脏病。没有一个被认为与器械或手术有关。JET + PCB在3年随访中具有相似的TLR自由度和ABI和RCC的改善,两臂之间的截肢或死亡率没有差异。JET + PCB组有TLR减少的趋势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Jetstream Atherectomy with Paclitaxel-Coated Balloons: 3-Year Outcomes of the Prospective Randomized JET-RANGER Study.

The JET-RANGER study (NCT03206762) was a multicenter (11 U.S. centers), randomized trial, core-lab adjudicated and designed to demonstrate the superiority of Jetstream + paclitaxel-coated balloon (JET + PCB) versus percutaneous transluminal angioplasty (PTA) + PCB in treating femoropopliteal arterial disease. The 1- and 2-year outcomes have been recently published. The 3-year outcome data are presented in this report. The JET-RANGER trial initially had 47 patients with 48 lesions. Thirty-one in the JET-PCB arm and 16 in the PTA + PCB arm (2:1 randomization). At 3-year follow-ups, there were 20 patients in the JET-PCB arm and 14 patients in the PTA + PCB arm. Kaplan-Meier survival analysis was performed to estimate the freedom from target lesion revascularization (TLR) at 3 years. Bailout stenting was not considered a TLR in this analysis. Statistical significance was determined by a p -value < 0.05. Freedom from TLR was statistically similar between the two groups at 3 years between JET + PCB and PTA + PCB (freedom from TLR was 88.0 vs. 67.8%, respectively, p  = 0.1380). There was also no significant difference in the change of ankle-brachial index (ABI) between the PTA + PCB and JET + PCB from baseline at 6 months ( p  = 0.7890), 1 year ( p  = 0.4070), 2 years ( p  = 0.7410), and 3 years ( p  = 0.8010). There was also no statistical difference between the JET + PCB and PTA + PCB arms for RCC improvement by one or more categories from baseline to 3 years ( p  = 0.8949). There were no minor or major amputations for either arm throughout the 3-year follow-up. Five JET + PCB patients died before the 3-year specified window and none in the PTA + PCB arm ( p  = 0.137). Two of the deaths were due to cancer and three due to cardiac causes. None were deemed related to the device or procedure. JET + PCB had similar freedom from TLR and improvement in ABI and RCC at 3-year follow-up with no difference in amputation or mortality between the 2 arms. A trend toward less TLR was seen in the JET + PCB arm.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Angiology
International Journal of Angiology PERIPHERAL VASCULAR DISEASE-
CiteScore
1.30
自引率
16.70%
发文量
57
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信